Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK exec joins Inspire

Executive Summary

Former GlaxoSmithKline Assistant General Counsel for R&D Business Development Transactions Joseph Spagnardi joins Inspire as deputy general counsel, a newly created position. Spagnardi reports to Inspire General Counsel Barry Pea...

You may also be interested in...



“A New TNBC Standard Of Care” – Trodelvy Could Vindicate Gilead’s $21bn Buyout

Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.

UK To Use COVID-19 Learnings To Speed Up Review Of Certain Other Trials

A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.

Amgen Takes on One of Cancer’s Toughest Challenges

Discusses KRAS G12C and the importance of biomarker testing in non-small cell lung cancer (NSCLC).

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel